A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Tempus AI, Inc. TEM

Promising (early) Health Tech sector · Tempus AI — precision-medicine data and diagnostics; fast-growing but not yet profitable.

Key quality signals

Revenue growth (YoY)69.8%

Gross margin69.6%

Gross profits / assets0.44

Rule of 4051.7

Net margin-18.1%

Cash runway (months)41.3

PEG—

P/S6.2

Risk flags

Burning cash — operating margin is negative.Heavy share dilution (>5%/yr) — your slice shrinks.Hyper-expansion — assets up ~38% in a year; aggressive expanders have historically lagged.

Positive signals

Growth accelerating — revenue growth sped up ~27 points year-on-year; acceleration is an early fundamental tell (annual data, so it's coarse).

Insider & analyst context

Insider 90-day: 0 cluster buyer(s), 7 seller(s). Insider selling is routine diversification, not a bearish signal.
Analyst mix: 5 strong-buy / 9 buy / 7 hold / 1 sell. Ratings are context, not a price target.

Similar Health Tech names

Intuitive Surgical, Inc.DexCom, Inc.Veeva Systems Inc.CRISPR Therapeutics AGIntellia Therapeutics, Inc.

← All Health Tech names · Open TEM in the interactive screener →

Data as of 2026-06-09 22:43 (end-of-day). How grades are computed →